For Clinical Effectiveness, Adherence, and Withdrawal in Epilepsy Care, keep in mind Greatest variability source: non-adherence (medication adherence <20% level variance), Carbamazepine: autoinduction at ~4 weeks; can worsen absence/myoclonic seizures, and Cenobamate: ~45% achieve ≥50% seizure reduction as add-on for refractory focal epilepsy when choosing therapy, counseling about risk, planning monitoring, and deciding when closer follow-up or escalation is needed.

Greatest variability source: non-adherence (medication adherence &lt,20% level variance); Carbamazepine: autoinduction at ~4 weeks, can worsen absence/myoclonic seizures; Cenobamate: ~45% achieve ≥50% seizure reduction as add-on for refractory focal epilepsy; Broad-spectrum agents: felbamate, lamotrigine, topiramate; Withdrawal seizure risk highest with barbiturates/benzodiazepines